pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Casgevy
drug · gene
save

exagamglogene autotemcel

Phase 3updated 6mo ago
by $VERX Vertex, Inc.🔗 ChEMBL
Phase 3
community read0 votes

Gene drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

indications

indications
Sickle Cell Disease

targets

B-cell lymphoma/leukemia 11A

all catalysts(0)

nothing on the calendar yet

News(10)

  • nChroma halves workforce, BioXcel lets execs go
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 2h ago
  • Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
    Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.
    biospace · 2d ago
  • Genetix’s genetic medicines are officially profitable, with $327M in sales YTD
    It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech…
    biospace · 2d ago
  • Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
    Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.
    biospace · 2d ago
  • Marrow sets out to challenge genetic medicines for severe blood diseases
    Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta tha…
    biopharma_dive · 2d ago
  • Marrow extracts $120M series B to advance preclinical blood disease therapy
    A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta th…
    fiercebiotech · 6d ago
  • Beam’s base editing therapy for sickle cell hits goal in pivotal trial
    The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
    biopharma_dive · 9d ago
  • Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
    Gearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…
    fiercebiotech · 9d ago
  • Vertex, ahead of FDA decision, calms fears surrounding kidney drug
    On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
    biopharma_dive · 16d ago
  • Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
    Former biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…
    biospace · 17d ago
view all news mentions →
brand
Casgevy
trade names
Casgevy
generic
exagamglogene autotemcel
MOA
B-cell lymphoma/leukemia 11A gene editing negative modulator
indication
Beta Thalassaemia
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 7h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?